[203Pb]VMT01 + [212Pb]VMT01 + Nivolumab
Phase 1/2Recruiting 1 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Melanoma (Skin)
Conditions
Recurrent Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV, Melanoma Stage III
Trial Timeline
Jun 1, 2023 → Dec 31, 2029
NCT ID
NCT05655312About [203Pb]VMT01 + [212Pb]VMT01 + Nivolumab
[203Pb]VMT01 + [212Pb]VMT01 + Nivolumab is a phase 1/2 stage product being developed by Perspective Therapeutics for Recurrent Melanoma (Skin). The current trial status is recruiting. This product is registered under clinical trial identifier NCT05655312. Target conditions include Recurrent Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV.
What happened to similar drugs?
6 of 20 similar drugs in Recurrent Melanoma (Skin) were approved
Approved (6) Terminated (0) Active (14)
Hype Score Breakdown
Clinical
9
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05655312 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Recurrent Melanoma (Skin)